Here's My Top Space Stock to Buy Right Now, And Why It's Better Than SpaceX

Rocket Lab reports Q2 revenue up 62% to $234M while narrowing losses to $0.08/share, supported by a $2.36B backlog (90 missions) and at least seven Neutron-specific commercial launches through 2029. The key bullish angle is capital discipline: Rocket Lab’s Q2 capex was $26M vs $32M a year ago, compared with SpaceX’s $18.3B capex (+554% y/y), largely tied to its $16B Colossus AI data center. Overall, the article frames Rocket Lab as the lower-spend, higher-upside alternative as Neutron approaches the launchpad late 2026, though both names remain risky/unprofitable.

Analysis

The investable edge here is not the backlog itself; it is the probability that Neutron turns RKLB from a small-launch services company into a credible medium-lift platform. If execution holds, the market can justify a higher multiple on forward revenue because cadence and payload class expand addressable demand, especially for defense and constellation customers that want a second source. The second-order winner is the broader U.S. launch supply chain: avionics, composite structures, and ground systems vendors get more durable volume if Neutron moves from prototype to repeatable production.

The main risk is that the market is pricing de-risking before it exists. In the next 1-3 months, any test delay or anomaly would likely compress the stock quickly because the story depends on schedule credibility more than backlog optics. Over 6-18 months, the real variable is not bookings but gross margin per launch and whether the company needs incremental dilution to fund development; that determines whether backlog converts into equity value or just more revenue.

The contrarian view is that investors may be over-weighting the comparison with a much larger private competitor and under-weighting the difference in business mix: a focused launch operator with modest capex can compound better than a capital-intensive platform story if it keeps execution tight. But the reverse is also true: a single slip in Neutron would expose how much of the valuation is based on optionality rather than current economics. The thesis is falsified if Neutron slips materially beyond the current target window or if first-launch cadence does not translate into margin expansion within 2-3 quarters after initial flights.

Key Decisions for Investors

• Long RKLB on any post-news pullback; thesis horizon 6-12 months. Best risk/reward is buying de-risking, not chasing headlines. Falsify if Neutron slips by more than two quarters or if launch-related margins fail to improve after first flights.
• Use RKLB Jan-2027 call spreads instead of stock if you want convexity with defined downside. The trade works only if the market starts capitalizing Neutron as a repeatable platform rather than a one-off test program.
• Pair trade: long RKLB / short a basket of higher-beta pre-profitability space names such as SPCE or LUNR. The relative-value case is that RKLB has the clearest path from backlog to operational proof, while weaker peers remain financing-dependent.
• Set an alert around the first Neutron launchpad milestone and first orbital attempt; if either is delayed, reduce exposure immediately. This is a schedule-driven catalyst, not a slow fundamental re-rate.